Analysts' Top 5 Price Targets of August 4, 2025
Reading Time: 4 minutes
Apellis Pharmaceuticals [US03753U1060] Citigroup reaffirms Buy rating and raises price target from $46 to $52 (126% upside potential) The recent approval of EMPAVELI by the US FDA for the treatment of rare kidney diseases such as C3 glomerulopathy (C3G) and primary IC-MPGN has been positively highlighted. Apellis' leading role in the field of complement therapy was emphasized. With two approved C3-targeted drugs for four severe diseases, the company is strategically well-positioned. Additionally, SYFOVRE, another key product from Apellis,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
